143654-59-5

Basic information

• Product Name: Methyl 3-(2-fluorophenyl)propanoate
• Synonyms: Methyl 3-(2-fluorophenyl)propanoate;Benzenepropanoic acid, 2-fluoro-, Methyl ester;Methyl 2-fluorobenzenepropanoate
• CAS NO: 143654-59-5
• Molecular Formula: C₁₀H₁₁FO₂
• Molecular Weight: 182.1915432
• Mol File: 143654-59-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 3-(2-fluorophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(2-fluorophenyl)propanoate(143654-59-5)
• EPA Substance Registry System: Methyl 3-(2-fluorophenyl)propanoate(143654-59-5)

Safety Data

• Hazardous Substances Data: 143654-59-5(Hazardous Substances Data)

Usage

Uses

Used in Fragrance Industry:
Methyl 3-(2-fluorophenyl)propanoate is used as a fragrance ingredient for its distinctive fruity scent, contributing to the overall aroma profile of perfumes and other scented products.
Used in Flavor Industry:
Methyl 3-(2-fluorophenyl)propanoate serves as a flavoring agent, enhancing the taste and aroma of various food and beverage products, providing a unique fruity note.
Used in Household Products:
Methyl 3-(2-fluorophenyl)propanoate is also utilized in the formulation of household products such as soaps and detergents, where it imparts a pleasant scent and contributes to the overall sensory experience of the product.

Upstream product

• 67-56-1 methanol 
• 1643-26-1 3-(2-fluorophenyl)propionic acid 
• 59845-58-8 C₁₀H₉FO₂ 
• 18944-77-9 2-fluorocinnamic acid 
• 446-52-6 2-Fluorobenzaldehyde 
• 104201-65-2 methyl (2E)-3-(2-fluorophenyl)prop-2-enoate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 186581-53-3 diazomethane 
• 451-69-4 2-fluorocinnamic acid 

Downstream Products

• 221631-40-9 dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate 
• 1269625-80-0 Cyclohexylmethyl-[5-(2-fluoro-benzyl)-2-pyridin-2-yl-pyrimidin-4-yl]-amine 
• 1269625-81-1 4-[5-(2-Fluoro-benzyl)-2-pyridin-2-yl-pyrimidin-4-yl]-morpholine 
• 1269625-82-2 5-(2-Fluoro-benzyl)-4-piperidin-1-yl-2-pyridin-2-yl-pyrimidine 
• 1269625-84-4 [5-(2-Fluoro-benzyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl-amine 
• 1269625-85-5 5-(2-Fluoro-benzyl)-4-(4-methyl-piperazin-1-yl)-2-pyridin-2-yl-pyrimidine 
• 1269625-79-7 Diethyl-[5-(2-fluoro-benzyl)-2-pyridin-2-yl-pyrimidin-4-yl]-amine 
• 1269625-77-5 [5-(2-Fluoro-benzyl)-2-pyridin-2-yl-pyrimidin-4-yl]-isopropyl-amine 
• 1269625-76-4 4-chloro-5-(2-fluoro-benzyl)-2-pyridin-3-yl-pyrimidine 
• 1269625-75-3 4-chloro-5-(2-fluoro-benzyl)-2-pyridin-2-yl-pyrimidine 
• 1269625-74-2 5-(2-fluoro-benzyl)-2-pyridin-3-yl-pyrimidin-4-ol 
• 1269625-73-1 5-(2-fluoro-benzyl)-2-pyridin-2-yl-pyrimidin-4-ol 

Relevant articles and documents

Reduction of Electron-Deficient Alkenes Enabled by a Photoinduced Hydrogen Atom Transfer

Direct hydrogen atom transfer from a photoredox-generated Hantzsch ester radical cation to electron-deficient alkenes has enabled the development of an efficient formal hydrogenation under mild, operationally simple conditions. The HAT-driven mechanism is supported by experimental and computational studies. The reaction is applied to a variety of cinnamate derivatives and related structures, irrespective of the presence of electron-donating or electron-withdrawing substituents in the aromatic ring and with good functional group compatibility. (Figure presented.).

Synthesis and inhibitory studies of phosphonic acid analogues of homophenylalanine and phenylalanine towards alanyl aminopeptidases

A library of novel phosphonic acid analogues of homophenylalanine and phenylalanine, containing fluorine and bromine atoms in the phenyl ring, have been synthesized. Their inhibitory properties against two important alanine aminopeptidases, of human (hAPN, CD13) and porcine (pAPN) origin, were evaluated. Enzymatic studies and comparison with literature data indicated the higher inhibitory potential of the homophenylalanine over phenylalanine derivatives towards both enzymes. Their inhibition constants were in the submicromolar range for hAPN and the micromolar range for pAPN, with 1-amino-3-(3-fluorophenyl) propylphosphonic acid (compound 15c) being one of the best low-molecular inhibitors of both enzymes. To the best of our knowledge, P1 homophenylalanine analogues are the most active inhibitors of the APN among phosphonic and phosphinic derivatives described in the literature. Therefore, they constitute interesting building blocks for the further design of chemically more complex inhibitors. Based on molecular modeling simulations and SAR (structure-activity relationship) analysis, the optimal architecture of enzyme-inhibitor complexes for hAPN and pAPN were determined.

Photodriven Transfer Hydrogenation of Olefins

An improved practical method for the photodriven diimide reduction of olefins was investigated. This catalyst-free procedure proceeds at ambient temperature, utilizes air as oxidant and a lower hydrazine loading, and produces inert nitrogen gas as the sole byproduct. Several functional groups were tolerated, and in some cases, the reaction was chemoselective. Challenging substrates such as cinnamate ester derivatives and trans-stilbene were reduced in excellent yields. The small amount of UVA rays emitted from a household compact fluorescent light bulb was proposed to enable the cis/trans isomerization of the diimide and to promote the loss of hydrogen from the diimide.

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, Y, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using theses compounds or the compositions containing them.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.

C11 oxymyl and hydroxylamino prostaglandins useful as medicaments

The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W,

Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chin aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2α). (C) 2000 Published by Elsevier Science Ltd.

Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: wherein R1, R2, R3, R4, X, Y, and Z are defined below. This invention also includes optical isomers,

Hexa-cyclic compound

A novel hexa-cyclic compound, a derivative of camptothecin, of the general formula: STR1 The compound is prepared from an aminoketone compound and a pyranoindolizine compound by the condensation-ring closing reaction. It is abundantly water-soluble, and has an excellent antitumour activity and a high degree of safety, and can be applied as an antitumour medicine for curing tumors of various kinds.